A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer

BACKGROUND: We assessed nofazinlimab, an anti-PD-1 antibody, in solid tumors and combined with regorafenib in metastatic colorectal cancer (mCRC). METHODS: This phase 1 study comprised nofazinlimab dose escalation (phase 1a) and expansion (phase 1b), and regorafenib dose escalation (80 or 120 mg QD,...

Descripción completa

Detalles Bibliográficos
Autores principales: Day, Daphne, Park, John J., Coward, Jermaine, Markman, Ben, Lemech, Charlotte, Kuo, James C., Prawira, Amy, Brown, Michael P., Bishnoi, Sarwan, Kotasek, Dusan, Strother, R. Matthew, Cosman, Rasha, Su, Rila, Ma, Yiding, Yue, Zenglian, Hu, Hui-han, Wu, Rachel, Li, Peiqi, Tse, Archie N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646086/
https://www.ncbi.nlm.nih.gov/pubmed/37731023
http://dx.doi.org/10.1038/s41416-023-02431-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646086/
https://www.ncbi.nlm.nih.gov/pubmed/37731023
http://dx.doi.org/10.1038/s41416-023-02431-7

Ejemplares similares